Search
Close this search box.

Ochre Bio: fully human, super speedy liver drug development

ARTICLE | Emerging Company Profile

Company is ditching animal models and designing biopsy-free trials

By Richard Guy, Biopharma Analyst

February 8, 2024 9:57 PM UTC

Liver disease company Ochre has a three-part system for validating siRNA therapeutic targets that relies entirely on human cells and tissues, sidestepping the problems of animal models. The company is also rethinking clinical trials, hoping to get proof-of-concept data quickly without using biopsy-based endpoints.

Based in Oxford, U.K., with additional labs in Taipei and New York, Ochre Bio Ltd. has raised $40 million across seed and series A rounds since its 2019 founding…